Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X2XZ
|
|||
| Former ID |
DIB019102
|
|||
| Drug Name |
CFI-400945
|
|||
| Synonyms |
CFI 400945; CFI400945
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H34N4O3
|
|||
| Canonical SMILES |
CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O
|
|||
| InChI |
1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1
|
|||
| InChIKey |
DADASRPKWOGKCU-FVTQAUBDSA-N
|
|||
| CAS Number |
CAS 1338806-73-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Polo-like kinase 4 (PLK4) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04176848) CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.